Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 77.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 609 shares of the biopharmaceutical company’s stock after selling 2,091 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Gilead Sciences were worth $56,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. Finally, Crews Bank & Trust bought a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $109.95 on Friday. The firm’s 50 day simple moving average is $95.41 and its 200-day simple moving average is $88.73. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $111.03. The company has a market cap of $137.03 billion, a P/E ratio of 297.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s payout ratio is presently 832.43%.

Analysts Set New Price Targets

GILD has been the topic of several recent research reports. Citigroup initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Oppenheimer lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.08.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 713,000 shares of company stock valued at $67,945,181. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.